^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) + Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).
Published date:
05/13/2020
Excerpt:
EGFR exon 19 deletions (Ex19del) or exon 21 substitution mutation (Ex21.L858R) received RAM (10 mg/kg Q2W) plus GEF (250 mg/day) until disease progression or unacceptable toxicity….The objective response rate was 70.7% (95% CI: 59.6–80.3), disease control rate was 98.8% (95% CI: 93.4–100.0)...
DOI:
10.1200/JCO.2020.38.15_suppl.9564
Trial ID:
Source:
Title:
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)
Excerpt:
Eligible for first-line treatment with erlotinib based on documented evidence of tumor harboring an activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation].
Trial ID:
Source:
Title:
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
Published date:
02/25/2022
Excerpt:
The 1-year PFS rate with RAM plus GEF was 62.9% (95% CI: 50.3–73.1); 2-year PFS rate was 26.1% (95% CI: 16.2–37.0) (Table 2). Median PFS was 14.1 months (95% CI: 12.3–17.9) (Fig. 3). Subgroup analyses for EGFR mutation type were performed; 1-year PFS rate (95% CI) was 67.2% (48.6–80.3) and 59.2% (41.4–73.3) for ex19del and ex21.L858R subgroups, respectively....RELAY+ revealed a favorable benefit–risk profile for RAM plus GEF in the first-line treatment of East Asian patients with EGFR-mutated NSCLC.
DOI:
https://doi.org/10.1016/j.jtocrr.2022.100303
Trial ID:
